The role of pseudolysogeny in bacteriophage-host interactions in a natural freshwater environment

The role of pseudolysogeny in bacteriophage-host interactions in a natural freshwater environment

Antibodies, Assay, Assay Kits, background, Biology Cells, cDNA, Characterization and formulation into solid dosage forms of a novel bacteriophage lytic against Klebsiella oxytoca., Clia Kits, Cross-genus rebooting of custom-made, synthetic bacteriophage genomes in L-form bacteria., Culture Cells, DNA, DNA Templates, Elisa Kits, Enzymes, Equipments, Exosomes, Gels, Medium & Serums, Microencapsulation of Salmonella-Specific Bacteriophage Felix O1 Using Spray-Drying in a pH-Responsive Formulation and Direct Compression Tableting of Powders into a Solid Oral Dosage Form., My Blog, NATtrol, Opossum, Particles, Pcr Kits, Peptides, Plant, primers, Reagents, Ria Kits, RNA, Vector & Virus, Western Blot / By
Bacteriophages happen in excessive numbers in environmental ecosystems and are thus vital mediators of microbial survival and actions. However, interactions between microbial populations and phages in situ have been largely ignored. Current understanding of the method depends on research carried out with well-fed, laboratory-grown host micro organism.
The objective of the experiments reported right here was to find out bacteriophage-host interactions underneath environmentally related circumstances of nutrient limitation. These research have revealed the significance of a phenomenon referred to as pseudolysogeny in the upkeep of viral genetic materials for prolonged intervals of time in natural ecosystems. Pseudolysogeny is a type of phage-host cell interplay in which the nucleic acid of the phage resides inside its starved host in an unstable, inactive state.
It is hypothesized that pseudolysogeny happens as a result of cell’s extremely starved situation. In such cells, there may be inadequate power obtainable for the phage to provoke genetic expression resulting in both a true temperate response or to the lytic response. However, upon nutrient addition, the pseudolysogenic state is resolved, ensuing in both the institution of true lysogeny or the initiation of the lytic manufacturing of progeny virions. The pseudolysogenic state could clarify the long-term survival of viruses in unfavourable environments in which the infective half-life of their virions is comparatively quick.

Antibody design utilizing LSTM based mostly deep generative mannequin from phage show library for affinity maturation

Molecular evolution is a vital step in the event of therapeutic antibodies. However, the present methodology of affinity maturation is overly pricey and labor-intensive as a result of of the repetitive mutation experiments wanted to adequately discover sequence house. Here, we employed a lengthy quick time period reminiscence community (LSTM)-a extensively used deep generative model-based sequence era and prioritization process to effectively uncover antibody sequences with larger affinity.
We utilized our methodology to the affinity maturation of antibodies towards kynurenine, which is a metabolite associated to the niacin synthesis pathway. Kynurenine binding sequences have been enriched by means of phage show panning utilizing a kynurenine-binding oriented human artificial Fab library. We outlined binding antibodies utilizing a sequence repertoire from the NGS information to coach the LSTM mannequin.
We confirmed that probability of generated sequences from a educated LSTM correlated nicely with binding affinity. The affinity of generated sequences are over 1800-fold larger than that of the parental clone. Moreover, in comparison with frequency based mostly screening utilizing the identical dataset, our machine studying method generated sequences with larger affinity.

Isolation, Characterization, and Application in Poultry Product of a Specific Salmonella Bacteriophage S55

Salmonellosis happens continuously worldwide, inflicting critical threats to public well being security. The abuse of antibiotics is rising the antibiotic resistance in micro organism, thereby making the prevention and management of Salmonella harder. A phage can assist management the unfold of micro organism. In this research, S55, a lytic phage, was remoted from faecal samples obtained from poultry farms utilizing Salmonella Pullorum ( S . Pullorum) because the host bacterium.
This phage belongs to Siphoviridae and has a polyhedral head and a retraction-free tail. S55 confirmed a robust capacity to lyse Salmonella serovars, equivalent to S . Pullorum (58/60, 96.67%) and S . Enteritidis (97/104, 93.27%). One-step progress kinetics confirmed that the latent interval was 10 min, burst interval was 80 min and burst dimension was 40 pfu/cell. The optimum multiplicity of an infection was 0.01, and the phage was in a position to survive at a pH of 4-11 and temperature of 40°C-60°C for 60 min.
The role of pseudolysogeny in bacteriophage-host interactions in a natural freshwater environment
Complete genome sequence evaluation revealed that the S55 genome size is 42,781 bp (GC content material, 50.28%) and it comprises 58 open studying frames (ORF), together with 25 ORFs with identified or assumed features, with out tRNA genes. Moreover, S55 doesn’t carry genes that encode virulence or resistance components. At totally different temperatures (4°C or 25°C), S55 was discovered to decrease the populations of S . Pullorum and S . Enteritidis on rooster pores and skin floor. Its bacteriostatic impact at 4°C was larger than that at 25°C. In conclusion, S55 may be thought of a promising organic agent for the prevention and management of Salmonella .

Assessment of bacteriophage vB_Pd_PDCC-1 on bacterial dynamics throughout ontogenetic growth of the longfin yellowtail (Seriola rivoliana)

The Seriola genus consists of species of worldwide business significance attributable to its speedy progress and straightforward adaptability to confinement circumstances. However, like different fish species, massive mortalities happen throughout their formative years phases, the place the primary issues are brought on by opportunistic micro organism.
Disease management methods are thus urgently wanted. The current research aimed to judge the efficacy of phage vB_Pd_PDCC-1 through the early growth of longfin yellowtail (Seriola rivoliana), in addition to its impact on microbial communities. This broad-host-range phage was added to the tradition each three days ranging from the egg-stage till 12 days after hatching (DAH) at a focus of 1.41×1010 plaque-forming models (PFU) per mL and at a multiplicity of an infection (MOI) of 1. The outcomes confirmed constructive results (p<0.05) on egg hatching, survival, progress, and pigmentation space in handled larvae.
Moreover, high-throughput sequencing evaluation of 16S rRNA genes confirmed that phage administration didn’t produce vital modifications (p>0.05) in the composition and construction of the related microbiota. However, sequences affiliated to the Gammaproteobacteria class have been displaced by these belonging to the Alphaproteobacteria class over time regardless of the therapy obtained. At the household stage, there was a lower in Rhodobacteraceae, Pseudoalteromonadaceae, and Flavobacteriaceae in each teams over time.

Anti-human CD38 Monoclonal Antibody Biotin Conjugated, Flow Validated
FC00193-Biotin 100µg
EUR 152
Description: Mouse Monoclonal human CD38 Antibody Biotin Conjugated, Flow Validated. Validated in Flow Cytometry and tested in Human.

Anti-human CD25 Monoclonal Antibody Biotin Conjugated, Flow Validated
FC00214-Biotin 100µg
EUR 233
Description: Mouse Monoclonal human CD25 Antibody Biotin Conjugated, Flow Validated. Validated in Flow Cytometry and tested in Human.

Anti-human CD4 Monoclonal Antibody Biotin Conjugated, Flow Validated
FC00344-Biotin 100µg
EUR 152
Description: Mouse Monoclonal human CD4 Antibody Biotin Conjugated, Flow Validated. Validated in Flow Cytometry and tested in Human.

Anti-human CD5 Monoclonal Antibody Biotin Conjugated, Flow Validated
FC00480-Biotin 100µg
EUR 233
Description: Mouse Monoclonal human CD5 Antibody Biotin Conjugated, Flow Validated. Validated in Flow Cytometry and tested in Human.

Anti-human CD45 Monoclonal Antibody Biotin Conjugated, Flow Validated
FC00555-Biotin 100µg
EUR 152
Description: Mouse Monoclonal human CD45 Antibody Biotin Conjugated, Flow Validated. Validated in Flow Cytometry and tested in Human.

Anti-human CD2 Monoclonal Antibody Biotin Conjugated, Flow Validated
FC00570-Biotin 100µg
EUR 233
Description: Mouse Monoclonal human CD2 Antibody Biotin Conjugated, Flow Validated. Validated in Flow Cytometry and tested in Human.

Anti-human CD71 Monoclonal Antibody Biotin Conjugated, Flow Validated
FC00591-Biotin 100µg
EUR 245
Description: Mouse Monoclonal human CD71 Antibody Biotin Conjugated, Flow Validated. Validated in Flow Cytometry and tested in Human.

Anti-human CD62L Monoclonal Antibody Biotin Conjugated, Flow Validated
FC00652-Biotin 100µg
EUR 233
Description: Mouse Monoclonal human CD62L Antibody Biotin Conjugated, Flow Validated. Validated in Flow Cytometry and tested in Human.

Anti-human CD59 Monoclonal Antibody Biotin Conjugated, Flow Validated
FC00914-Biotin 100µg
EUR 265
Description: Mouse Monoclonal human CD59 Antibody Biotin Conjugated, Flow Validated. Validated in Flow Cytometry and tested in Human.

Anti-human CD117 Monoclonal Antibody Biotin Conjugated, Flow Validated
FC01335-Biotin 100μg
EUR 224
Description: Mouse Monoclonal human CD117 Antibody Biotin Conjugated, Flow Validated. Validated in Flow Cytometry and tested in Human.

Anti-human CD32 Monoclonal Antibody Biotin Conjugated, Flow Validated
FC01450-Biotin 100µg
EUR 233
Description: Mouse Monoclonal human CD32 Antibody Biotin Conjugated, Flow Validated. Validated in Flow Cytometry and tested in Human.

Anti-human CD90 Monoclonal Antibody Biotin Conjugated, Flow Validated
FC01818-Biotin 100µg
EUR 268
Description: Mouse Monoclonal human CD90 Antibody Biotin Conjugated, Flow Validated. Validated in Flow Cytometry and tested in Human.

Anti-human CD7 Monoclonal Antibody Biotin Conjugated, Flow Validated
FC01974-Biotin 100µg
EUR 233
Description: Mouse Monoclonal human CD7 Antibody Biotin Conjugated, Flow Validated. Validated in Flow Cytometry and tested in Human.

Anti-human CD235a Monoclonal Antibody Biotin Conjugated, Flow Validated
FC02184-Biotin 100µg
EUR 245
Description: Mouse Monoclonal human CD235a Antibody Biotin Conjugated, Flow Validated. Validated in Flow Cytometry and tested in Human.

Anti-human CD8 Monoclonal Antibody Biotin Conjugated, Flow Validated
FC02236-Biotin 100µg
EUR 152
Description: Mouse Monoclonal human CD8 Antibody Biotin Conjugated, Flow Validated. Validated in Flow Cytometry and tested in Human.

Anti-Human VEGI Monoclonal Antibody Biotin Conjugated, Flow Validated
FC02402-Biotin Various Sizes
EUR 497
Description: Mouse Monoclonal Human VEGI Antibody Biotin Conjugated, Flow Validated. Validated in WB and tested in Human.

Anti-human CD3 Monoclonal Antibody Biotin Conjugated, Flow Validated
FC02675-Biotin 100µg
EUR 152
Description: Mouse Monoclonal human CD3 Antibody Biotin Conjugated, Flow Validated. Validated in Flow Cytometry and tested in Human.

Anti-human CD20 Monoclonal Antibody Biotin Conjugated, Flow Validated
FC03780-Biotin 100µg
EUR 233
Description: Mouse Monoclonal human CD20 Antibody Biotin Conjugated, Flow Validated. Validated in Flow Cytometry and tested in Human.

Anti-human CD10 Monoclonal Antibody Biotin Conjugated, Flow Validated
FC04065-Biotin 100µg
EUR 189
Description: Mouse Monoclonal human CD10 Antibody Biotin Conjugated, Flow Validated. Validated in Flow Cytometry and tested in Human.

Anti-human CD57 Monoclonal Antibody Biotin Conjugated, Flow Validated
FC09548-Biotin 100µg
EUR 245
Description: Mouse Monoclonal human CD57 Antibody Biotin Conjugated, Flow Validated. Validated in Flow Cytometry and tested in Human.

Anti-human HLA-DR Monoclonal Antibody Biotin Conjugated, Flow Validated
FC00568-Biotin 100µg
EUR 233
Description: Mouse Monoclonal human HLA-DR Antibody Biotin Conjugated, Flow Validated. Validated in Flow Cytometry and tested in Human.

Anti-human CD55/Daf Monoclonal Antibody Biotin Conjugated, Flow Validated
FC00910-Biotin 100µg
EUR 233
Description: Mouse Monoclonal human CD55/Daf Antibody Biotin Conjugated, Flow Validated. Validated in Flow Cytometry and tested in Human.

Anti-human CD33/Siglec 3 Monoclonal Antibody Biotin Conjugated, Flow Validated
FC01508-Biotin 100µg
EUR 234
Description: Mouse Monoclonal human CD33/Siglec 3 Antibody Biotin Conjugated, Flow Validated. Validated in Flow Cytometry and tested in Human.

Anti-human CD22/Siglec 2 Monoclonal Antibody Biotin Conjugated, Flow Validated
FC01572-Biotin 100µg
EUR 233
Description: Mouse Monoclonal human CD22/Siglec 2 Antibody Biotin Conjugated, Flow Validated. Validated in Flow Cytometry and tested in Human.

M13/fd/F1 Filamentous Phages antibody (Biotin)
10R-2378 50 ug
EUR 194
Description: Mouse monoclonal M13/fd/F1 antibody

M13 + fd + F1 Filamentous Phages antibody (biotin)
61R-M101aBT 250 uL
EUR 531
Description: Mouse monoclonal M13 + fd + F1 Filamentous Phages antibody (biotin)

Mouse anti-human CD7 Monoclonal Antibody Biotin Conjugated, Flow Validated
FC01974-1-Biotin 100µg
EUR 233
Description: Mouse Monoclonal Mouse human CD7 Antibody Biotin Conjugated, Flow Validated. Validated in Flow Cytometry and tested in Human.

M13 phage antibody
10R-8063 100 ug
EUR 403
Description: Mouse monoclonal M13 phage antibody

M13 phage antibody
10R-8064 100 ug
EUR 403
Description: Mouse monoclonal M13 phage antibody

CX3CR1 Antibody (biotin)
2093-biotin-002mg 0.02 mg
EUR 171.82
Description: CX3CR1 Antibody: CX3CR1 is one of the chemokine receptors that are required as coreceptors for HIV infection. The genes encoding human, murine, and rat CX3CR1 were cloned and designated V28 and CMKBRL1, CX3CR1, and RBS11, respectively. The encoded seven transmembrane protein was recently identified as the receptor for a novel transmembrane molecule, fractalkine, and renamed CX3CR1. Recently, CX3CR1 was found to serve as a coreceptor for HIV-1 and HIV-2 envelope fusion and virus infection, which can be inhibited by fractokine. CX3CR1 mediates leukocyte migration and adhesion. CX3CR1 is expressed in a variety of human tissues and cell lines.

CX3CR1 Antibody (biotin)
2093-biotin-01mg 0.1 mg
EUR 436.42
Description: CX3CR1 Antibody: CX3CR1 is one of the chemokine receptors that are required as coreceptors for HIV infection. The genes encoding human, murine, and rat CX3CR1 were cloned and designated V28 and CMKBRL1, CX3CR1, and RBS11, respectively. The encoded seven transmembrane protein was recently identified as the receptor for a novel transmembrane molecule, fractalkine, and renamed CX3CR1. Recently, CX3CR1 was found to serve as a coreceptor for HIV-1 and HIV-2 envelope fusion and virus infection, which can be inhibited by fractokine. CX3CR1 mediates leukocyte migration and adhesion. CX3CR1 is expressed in a variety of human tissues and cell lines.

ACE2 Antibody (biotin)
3217-biotin-002mg 0.02 mg
EUR 191.42
Description: ACE2 Antibody: Angiotensin-converting enzyme 2 (ACE2) plays a central role in vascular, renal, and myocardial physiology. In contrast to its homolog ACE, ACE2 expression is restricted to heart, kidney, and testis. Recently. ACE2 has also been shown to be a functional receptor of the SARS coronavirus. Homology modeling shows 2019-nCoV has a similar receptor-binding domain structure as SARS-CoV, which suggests COVID-19 (2019-nCoV) may use ACE2 as a receptor in humans for infection. The normal function of ACE2 is to convert the inactive vasoconstrictor angiotensin I (AngI) to Ang1-9 and the active form AngII to Ang1-7, unlike ACE, which converts AngI to AngII. While the role of these vasoactive peptides is not well understood, lack of ACE2 expression in ace2-/ace2- mice leads to severely reduced cardiac contractility, indicating its importance in regulating heart function.

ACE2 Antibody (biotin)
3217-biotin-01mg 0.1 mg
EUR 495.22
Description: ACE2 Antibody: Angiotensin-converting enzyme 2 (ACE2) plays a central role in vascular, renal, and myocardial physiology. In contrast to its homolog ACE, ACE2 expression is restricted to heart, kidney, and testis. Recently. ACE2 has also been shown to be a functional receptor of the SARS coronavirus. Homology modeling shows 2019-nCoV has a similar receptor-binding domain structure as SARS-CoV, which suggests COVID-19 (2019-nCoV) may use ACE2 as a receptor in humans for infection. The normal function of ACE2 is to convert the inactive vasoconstrictor angiotensin I (AngI) to Ang1-9 and the active form AngII to Ang1-7, unlike ACE, which converts AngI to AngII. While the role of these vasoactive peptides is not well understood, lack of ACE2 expression in ace2-/ace2- mice leads to severely reduced cardiac contractility, indicating its importance in regulating heart function.

PD1 Antibody [7H6] (biotin)
RF16003-biotin-002mg 0.02 mg
EUR 191.42
Description: Cell-mediated immune responses are initiated by T lymphocytes that are themselves stimulated by cognate peptides bound to MHC molecules on antigen-presenting cells (APC). T-cell activation is generally self-limited as activated T cells express receptors such as PD-1 (also known as PDCD-1) that mediate inhibitory signals from the APC. PD-1 can bind two different but related ligands, PDL-1 and PDL-2. Upon binding to either of these ligands, signals generated by PD-1 inhibit the activation of the immune response in the absence of "danger signals" such as LPS or other molecules associated with bacteria or other pathogens. Evidence for this is seen in PD-1-null mice who exhibit hyperactivated immune systems and autoimmune diseases. PD-1 is thus one of a growing number of immune checkpoint proteins.

PD1 Antibody [7H6] (biotin)
RF16003-biotin-01mg 0.1 mg
EUR 495.22
Description: Cell-mediated immune responses are initiated by T lymphocytes that are themselves stimulated by cognate peptides bound to MHC molecules on antigen-presenting cells (APC). T-cell activation is generally self-limited as activated T cells express receptors such as PD-1 (also known as PDCD-1) that mediate inhibitory signals from the APC. PD-1 can bind two different but related ligands, PDL-1 and PDL-2. Upon binding to either of these ligands, signals generated by PD-1 inhibit the activation of the immune response in the absence of "danger signals" such as LPS or other molecules associated with bacteria or other pathogens. Evidence for this is seen in PD-1-null mice who exhibit hyperactivated immune systems and autoimmune diseases. PD-1 is thus one of a growing number of immune checkpoint proteins.

PDL1 Antibody [8E12] (biotin)
RF16032-biotin-002mg 0.02 mg
EUR 191.42
Description: PD-L1 Antibody: Cell-mediated immune responses are initiated by T lymphocytes that are themselves stimulated by cognate peptides bound to MHC molecules on antigen-presenting cells (APC) (1). T-cell activation is generally self-limited as activated T cells express receptors such as PD-1 (also known as PDCD-1) that mediate inhibitory signals from the APC (2). PD-1 can bind two different but related ligands, PD-L1 and PD-L2. PD-L1 is a B7-related protein that inhibits cell-mediated immune responses by reducing the secretion of IL-2 and IL-10 from memory T cells (3). This suggests that PD-L1 may be useful in reducing allogenic CD4+ memory T-cell responses to endothelial cells, thereby reducing the likelihood of host immune responses to allografts. PD-L1 also functions as an immune checkpoint protein, and multiple anti-PD-L1 antibodies are currently in phase II and III clinical trials, with one antibody already approved for the treatment of cancer (4).

PDL1 Antibody [8E12] (biotin)
RF16032-biotin-01mg 0.1 mg
EUR 495.22
Description: PD-L1 Antibody: Cell-mediated immune responses are initiated by T lymphocytes that are themselves stimulated by cognate peptides bound to MHC molecules on antigen-presenting cells (APC) (1). T-cell activation is generally self-limited as activated T cells express receptors such as PD-1 (also known as PDCD-1) that mediate inhibitory signals from the APC (2). PD-1 can bind two different but related ligands, PD-L1 and PD-L2. PD-L1 is a B7-related protein that inhibits cell-mediated immune responses by reducing the secretion of IL-2 and IL-10 from memory T cells (3). This suggests that PD-L1 may be useful in reducing allogenic CD4+ memory T-cell responses to endothelial cells, thereby reducing the likelihood of host immune responses to allografts. PD-L1 also functions as an immune checkpoint protein, and multiple anti-PD-L1 antibodies are currently in phase II and III clinical trials, with one antibody already approved for the treatment of cancer (4).

TIGIT Antibody [10B1] (biotin)
RF16058-biotin-002mg 0.02 mg
EUR 191.42
Description: TIGIT Antibody: The T cell immunoreceptor with Ig and ITIM domains (TIGIT) is a member of the PVR (poliovirus receptor) family of immunoglobin proteins. It is expressed on several classes of T cells including follicular B helper T cells (TFH). TIGIT has been shown to bind PVR with high affinity; this binding is thought to assist interactions between TFH and dendritic cells to regulate T cell dependent B cell responses (1). Similar to other immune checkpoint proteins such as PD-1, TIGIT is upregulated on exhausted T cells in chronic viral infections and cancer. Blockade of both TIGIT and PD-1 pathways leads to tumor rejection in mice suggesting that it may be of therapeutic use against cancer (2).

TIGIT Antibody [10B1] (biotin)
RF16058-biotin-01mg 0.1 mg
EUR 495.22
Description: TIGIT Antibody: The T cell immunoreceptor with Ig and ITIM domains (TIGIT) is a member of the PVR (poliovirus receptor) family of immunoglobin proteins. It is expressed on several classes of T cells including follicular B helper T cells (TFH). TIGIT has been shown to bind PVR with high affinity; this binding is thought to assist interactions between TFH and dendritic cells to regulate T cell dependent B cell responses (1). Similar to other immune checkpoint proteins such as PD-1, TIGIT is upregulated on exhausted T cells in chronic viral infections and cancer. Blockade of both TIGIT and PD-1 pathways leads to tumor rejection in mice suggesting that it may be of therapeutic use against cancer (2).

TIM3 Antibody [10C10] (biotin)
RF16103-biotin-002mg 0.02 mg
EUR 191.42
Description: The immune checkpoint protein TIM3 is a member of the immunoglobulin superfamily and TIM family of proteins that was initially identified as a specific marker of fully differentiated IFN-γ producing CD4 T helper 1 (Th1) and CD8 cytotoxic cells. It is a Th1-specific cell surface protein that regulates macrophage activation and negatively regulates Th1-mediated auto- and alloimmune responses, and is also highly expressed on regulatory T cells, monocytes, macrophages, and dendritic cells (1). TIM3 and PD-1 are co-expressed on most CD4 and CD8 T cells infiltrating solid tumors or in hematologic malignancy in mice; blocking TIM3 in conjugation with a PD-1 blockade increases the functionality of exhausted T cells and synergizes with to inhibit tumor growth (2,3).

TIM3 Antibody [10C10] (biotin)
RF16103-biotin-01mg 0.1 mg
EUR 495.22
Description: The immune checkpoint protein TIM3 is a member of the immunoglobulin superfamily and TIM family of proteins that was initially identified as a specific marker of fully differentiated IFN-γ producing CD4 T helper 1 (Th1) and CD8 cytotoxic cells. It is a Th1-specific cell surface protein that regulates macrophage activation and negatively regulates Th1-mediated auto- and alloimmune responses, and is also highly expressed on regulatory T cells, monocytes, macrophages, and dendritic cells (1). TIM3 and PD-1 are co-expressed on most CD4 and CD8 T cells infiltrating solid tumors or in hematologic malignancy in mice; blocking TIM3 in conjugation with a PD-1 blockade increases the functionality of exhausted T cells and synergizes with to inhibit tumor growth (2,3).

CDw17(HuLy-m13) Antibody
BNCA1088-250 250uL
EUR 383
Description: Primary antibody against CDw17(HuLy-m13), APC conjugate, Concentration: 0.1mg/mL

CDw17(HuLy-m13) Antibody
BNC811088-100 100uL
EUR 199
Description: Primary antibody against CDw17(HuLy-m13), CF680R conjugate, Concentration: 0.1mg/mL

CDw17(HuLy-m13) Antibody
BNC811088-500 500uL
EUR 544
Description: Primary antibody against CDw17(HuLy-m13), CF680R conjugate, Concentration: 0.1mg/mL

CDw17(HuLy-m13) Antibody
BNCAP1088-100 100uL
EUR 199
Description: Primary antibody against CDw17(HuLy-m13), Alkaline Phosphatase conjugate, Concentration: 0.1mg/mL

CDw17(HuLy-m13) Antibody
BNCAP1088-500 500uL
EUR 544
Description: Primary antibody against CDw17(HuLy-m13), Alkaline Phosphatase conjugate, Concentration: 0.1mg/mL

CDw17(HuLy-m13) Antibody
BNCB1088-100 100uL
EUR 199
Description: Primary antibody against CDw17(HuLy-m13), Biotin conjugate, Concentration: 0.1mg/mL

CDw17(HuLy-m13) Antibody
BNCB1088-500 500uL
EUR 544
Description: Primary antibody against CDw17(HuLy-m13), Biotin conjugate, Concentration: 0.1mg/mL

CDw17(HuLy-m13) Antibody
BNC471088-100 100uL
EUR 199
Description: Primary antibody against CDw17(HuLy-m13), CF647 conjugate, Concentration: 0.1mg/mL

CDw17(HuLy-m13) Antibody
BNC471088-500 500uL
EUR 544
Description: Primary antibody against CDw17(HuLy-m13), CF647 conjugate, Concentration: 0.1mg/mL

CDw17(HuLy-m13) Antibody
BNC551088-100 100uL
EUR 199
Description: Primary antibody against CDw17(HuLy-m13), CF555 conjugate, Concentration: 0.1mg/mL

CDw17(HuLy-m13) Antibody
BNC551088-500 500uL
EUR 544
Description: Primary antibody against CDw17(HuLy-m13), CF555 conjugate, Concentration: 0.1mg/mL

CDw17(HuLy-m13) Antibody
BNC431088-100 100uL
EUR 199
Description: Primary antibody against CDw17(HuLy-m13), CF543 conjugate, Concentration: 0.1mg/mL

CDw17(HuLy-m13) Antibody
BNC431088-500 500uL
EUR 544
Description: Primary antibody against CDw17(HuLy-m13), CF543 conjugate, Concentration: 0.1mg/mL

CDw17(HuLy-m13) Antibody
BNC881088-100 100uL
EUR 199
Description: Primary antibody against CDw17(HuLy-m13), CF488A conjugate, Concentration: 0.1mg/mL

CDw17(HuLy-m13) Antibody
BNC881088-500 500uL
EUR 544
Description: Primary antibody against CDw17(HuLy-m13), CF488A conjugate, Concentration: 0.1mg/mL

CDw17(HuLy-m13) Antibody
BNC941088-100 100uL
EUR 199
Description: Primary antibody against CDw17(HuLy-m13), CF594 conjugate, Concentration: 0.1mg/mL

CDw17(HuLy-m13) Antibody
BNC941088-500 500uL
EUR 544
Description: Primary antibody against CDw17(HuLy-m13), CF594 conjugate, Concentration: 0.1mg/mL

CDw17(HuLy-m13) Antibody
BNCH1088-100 100uL
EUR 199
Description: Primary antibody against CDw17(HuLy-m13), Horseradish Peroxidase conjugate, Concentration: 0.1mg/mL

CDw17(HuLy-m13) Antibody
BNCH1088-500 500uL
EUR 544
Description: Primary antibody against CDw17(HuLy-m13), Horseradish Peroxidase conjugate, Concentration: 0.1mg/mL

CDw17(HuLy-m13) Antibody
BNCP1088-250 250uL
EUR 383
Description: Primary antibody against CDw17(HuLy-m13), PerCP conjugate, Concentration: 0.1mg/mL

CDw17(HuLy-m13) Antibody
BNC041088-100 100uL
EUR 199
Description: Primary antibody against CDw17(HuLy-m13), CF405S conjugate, Concentration: 0.1mg/mL

CDw17(HuLy-m13) Antibody
BNC041088-500 500uL
EUR 544
Description: Primary antibody against CDw17(HuLy-m13), CF405S conjugate, Concentration: 0.1mg/mL

CDw17(HuLy-m13) Antibody
BNCR1088-250 250uL
EUR 383
Description: Primary antibody against CDw17(HuLy-m13), RPE conjugate, Concentration: 0.1mg/mL

CDw17(HuLy-m13) Antibody
BNUB1088-100 100uL
EUR 209
Description: Primary antibody against CDw17(HuLy-m13), Concentration: 0.2mg/mL

CDw17(HuLy-m13) Antibody
BNUB1088-500 500uL
EUR 458
Description: Primary antibody against CDw17(HuLy-m13), Concentration: 0.2mg/mL

CDw17(HuLy-m13) Antibody
BNC681088-100 100uL
EUR 199
Description: Primary antibody against CDw17(HuLy-m13), CF568 conjugate, Concentration: 0.1mg/mL

CDw17(HuLy-m13) Antibody
BNC681088-500 500uL
EUR 544
Description: Primary antibody against CDw17(HuLy-m13), CF568 conjugate, Concentration: 0.1mg/mL

CDw17(HuLy-m13) Antibody
BNC701088-100 100uL
EUR 199
Description: Primary antibody against CDw17(HuLy-m13), CF770 conjugate, Concentration: 0.1mg/mL

CDw17(HuLy-m13) Antibody
BNC701088-500 500uL
EUR 544
Description: Primary antibody against CDw17(HuLy-m13), CF770 conjugate, Concentration: 0.1mg/mL

CDw17(HuLy-m13) Antibody
BNC051088-100 100uL
EUR 199
Description: Primary antibody against CDw17(HuLy-m13), CF405M conjugate, Concentration: 0.1mg/mL

CDw17(HuLy-m13) Antibody
BNC051088-500 500uL
EUR 544
Description: Primary antibody against CDw17(HuLy-m13), CF405M conjugate, Concentration: 0.1mg/mL

CDw17(HuLy-m13) Antibody
BNC611088-100 100uL
EUR 199
Description: Primary antibody against CDw17(HuLy-m13), CF660R conjugate, Concentration: 0.1mg/mL

CDw17(HuLy-m13) Antibody
BNC611088-500 500uL
EUR 544
Description: Primary antibody against CDw17(HuLy-m13), CF660R conjugate, Concentration: 0.1mg/mL

CDw17(HuLy-m13) Antibody
BNC401088-100 100uL
EUR 199
Description: Primary antibody against CDw17(HuLy-m13), CF640R conjugate, Concentration: 0.1mg/mL

CDw17(HuLy-m13) Antibody
BNC401088-500 500uL
EUR 544
Description: Primary antibody against CDw17(HuLy-m13), CF640R conjugate, Concentration: 0.1mg/mL

CDw17(HuLy-m13) Antibody
BNC801088-100 100uL
EUR 199
Description: Primary antibody against CDw17(HuLy-m13), CF680 conjugate, Concentration: 0.1mg/mL

CDw17(HuLy-m13) Antibody
BNC801088-500 500uL
EUR 544
Description: Primary antibody against CDw17(HuLy-m13), CF680 conjugate, Concentration: 0.1mg/mL

CDw17(HuLy-m13) Antibody
BNUM1088-50 50uL
EUR 395
Description: Primary antibody against CDw17(HuLy-m13), 1mg/mL

SARS-CoV-2 (COVID-19) Spike Antibody (biotin)
3525-biotin-002mg 0.02 mg
EUR 191.42
Description: Coronavirus disease 2019 (COVID-19), formerly known as 2019-nCoV acute respiratory disease, is an infectious disease caused by SARS-CoV-2, a virus closely related to the SARS virus (1). The disease is the cause of the 2019–20 coronavirus outbreak (2). The structure of 2019-nCoV consists of the following: a Spike protein (S), hemagglutinin-esterease dimer (HE), a membrane glycoprotein (M), an envelope protein (E) a nucleoclapid protein (N) and RNA. Coronavirus invades cells through Spike (S) glycoproteins, a class I fusion protein. It is the major viral surface protein that coronavirus uses to bind to the human cell surface receptor. It also mediates the fusion of host and viral cell membrane, allowing the virus to enter human cells and begin infection (3). The spike protein is the major target for neutralizing antibodies and vaccine development (4). The protein modeling suggests that there is strong interaction between Spike protein receptor-binding domain and its host receptor angiotensin-converting enzyme 2 (ACE2), which regulate both the cross-species and human-to-human transmissions of COVID-19 (5). The recent study has shown that the SARS-CoV-2 spike protein binds ACE2 with higher affinity than SARS-CoV spike protein (6).

SARS-CoV-2 (COVID-19) Spike Antibody (biotin)
3525-biotin-01mg 0.1 mg
EUR 495.22
Description: Coronavirus disease 2019 (COVID-19), formerly known as 2019-nCoV acute respiratory disease, is an infectious disease caused by SARS-CoV-2, a virus closely related to the SARS virus (1). The disease is the cause of the 2019–20 coronavirus outbreak (2). The structure of 2019-nCoV consists of the following: a Spike protein (S), hemagglutinin-esterease dimer (HE), a membrane glycoprotein (M), an envelope protein (E) a nucleoclapid protein (N) and RNA. Coronavirus invades cells through Spike (S) glycoproteins, a class I fusion protein. It is the major viral surface protein that coronavirus uses to bind to the human cell surface receptor. It also mediates the fusion of host and viral cell membrane, allowing the virus to enter human cells and begin infection (3). The spike protein is the major target for neutralizing antibodies and vaccine development (4). The protein modeling suggests that there is strong interaction between Spike protein receptor-binding domain and its host receptor angiotensin-converting enzyme 2 (ACE2), which regulate both the cross-species and human-to-human transmissions of COVID-19 (5). The recent study has shown that the SARS-CoV-2 spike protein binds ACE2 with higher affinity than SARS-CoV spike protein (6).

SARS-CoV-2 (COVID-19) Envelope Antibody (biotin)
3531-biotin-002mg 0.02 mg
EUR 191.42
Description: Coronavirus disease 2019 (COVID-19), formerly known as 2019-nCoV acute respiratory disease, is an infectious disease caused by SARS-CoV-2, a virus closely related to the SARS virus (1). The disease is the cause of the 2019–20 coronavirus outbreak (2). The structure of 2019-nCoV consists of the following: a spike protein (S), hemagglutinin-esterease dimer (HE), a membrane glycoprotein (M), an envelope protein (E) a nucleoclapid protein (N) and RNA. Envelope protein is a small polypeptide that contains at least one alpha-helical transmembrane domain. It involves in several aspects of the virus's life cycle, such as assembly, budding, envelope formation, and pathogenesis. E protein has membrane permeabilizing activity, which provides a possible rationale to inhibit in vitro ion channel activity of some synthetic coronavirus E proteins, and also viral replication (3).

SARS-CoV-2 (COVID-19) Envelope Antibody (biotin)
3531-biotin-01mg 0.1 mg
EUR 495.22
Description: Coronavirus disease 2019 (COVID-19), formerly known as 2019-nCoV acute respiratory disease, is an infectious disease caused by SARS-CoV-2, a virus closely related to the SARS virus (1). The disease is the cause of the 2019–20 coronavirus outbreak (2). The structure of 2019-nCoV consists of the following: a spike protein (S), hemagglutinin-esterease dimer (HE), a membrane glycoprotein (M), an envelope protein (E) a nucleoclapid protein (N) and RNA. Envelope protein is a small polypeptide that contains at least one alpha-helical transmembrane domain. It involves in several aspects of the virus's life cycle, such as assembly, budding, envelope formation, and pathogenesis. E protein has membrane permeabilizing activity, which provides a possible rationale to inhibit in vitro ion channel activity of some synthetic coronavirus E proteins, and also viral replication (3).

SARS-CoV-2 (COVID-19) Nucleocapsid Antibody (biotin)
9099-biotin-002mg 0.02 mg
EUR 191.42
Description: Coronavirus disease 2019 (COVID-19), formerly known as 2019-nCoV acute respiratory disease, is an infectious disease caused by SARS-CoV-2, a virus closely related to the SARS virus. The disease is the cause of the 2019–20 coronavirus outbreak (1). SARS-CoV-2 is the seventh member of the enveloped, positive-stranded RNA viruses that are able to infect humans. The SARS-CoV-2 genome, like other coronaviruses, encodes for multiple structural and nonstructural proteins. The structural proteins include spike protein (S), envelope protein (E), membrane glycoprotein (M), nucleocapsid phosphoprotein (N), and the nonstructural proteins include open reading frame 1ab (ORF1ab), ORF3a, ORF6, ORF7a, ORF8, and ORF10 (2). Nucleocapsid (N) protein is the most abundant protein of coronavirus. It is also one of the major structural proteins and is involved in the transcription and replication of viral RNA, packaging of the encapsidated genome into virions (3), and interference with cell cycle processes of host cells (4). Moreover, in many coronaviruses, including SARS-CoV, the N protein has high immunogenic activity and is abundantly expressed during infection (5). It can be detected in various patient samples including nasopharyngeal aspirate, urine, and fecal. Both S and N proteins may be potential antigens for serodiagnosis of COVID-19, just as many diagnostic methods have been developed for diagnosing SARS based on S and/or N proteins (6).

SARS-CoV-2 (COVID-19) Nucleocapsid Antibody (biotin)
9099-biotin-01mg 0.1 mg
EUR 495.22
Description: Coronavirus disease 2019 (COVID-19), formerly known as 2019-nCoV acute respiratory disease, is an infectious disease caused by SARS-CoV-2, a virus closely related to the SARS virus. The disease is the cause of the 2019–20 coronavirus outbreak (1). SARS-CoV-2 is the seventh member of the enveloped, positive-stranded RNA viruses that are able to infect humans. The SARS-CoV-2 genome, like other coronaviruses, encodes for multiple structural and nonstructural proteins. The structural proteins include spike protein (S), envelope protein (E), membrane glycoprotein (M), nucleocapsid phosphoprotein (N), and the nonstructural proteins include open reading frame 1ab (ORF1ab), ORF3a, ORF6, ORF7a, ORF8, and ORF10 (2). Nucleocapsid (N) protein is the most abundant protein of coronavirus. It is also one of the major structural proteins and is involved in the transcription and replication of viral RNA, packaging of the encapsidated genome into virions (3), and interference with cell cycle processes of host cells (4). Moreover, in many coronaviruses, including SARS-CoV, the N protein has high immunogenic activity and is abundantly expressed during infection (5). It can be detected in various patient samples including nasopharyngeal aspirate, urine, and fecal. Both S and N proteins may be potential antigens for serodiagnosis of COVID-19, just as many diagnostic methods have been developed for diagnosing SARS based on S and/or N proteins (6).

SARS-CoV-2 (COVID-19) Nucleocapsid Antibody (biotin)
9103-biotin-002mg 0.02 mg
EUR 191.42
Description: Coronavirus disease 2019 (COVID-19), formerly known as 2019-nCoV acute respiratory disease, is an infectious disease caused by SARS-CoV-2, a virus closely related to the SARS virus. The disease is the cause of the 2019–20 coronavirus outbreak (1). SARS-CoV-2 is the seventh member of the enveloped, positive-stranded RNA viruses that are able to infect humans. The SARS-CoV-2 genome, like other coronaviruses, encodes for multiple structural and nonstructural proteins. The structural proteins include spike protein (S), envelope protein (E), membrane glycoprotein (M), nucleocapsid phosphoprotein (N), and the nonstructural proteins include open reading frame 1ab (ORF1ab), ORF3a, ORF6, ORF7a, ORF8, and ORF10 (2). Nucleocapsid (N) protein is the most abundant protein of coronavirus. It is also one of the major structural proteins and is involved in the transcription and replication of viral RNA, packaging of the encapsidated genome into virions (3), and interference with cell cycle processes of host cells (4). Moreover, in many coronaviruses, including SARS-CoV, the N protein has high immunogenic activity and is abundantly expressed during infection (5). It can be detected in various patient samples including nasopharyngeal aspirate, urine, and fecal. Both S and N proteins may be potential antigens for serodiagnosis of COVID-19, just as many diagnostic methods have been developed for diagnosing SARS based on S and/or N proteins (6).

SARS-CoV-2 (COVID-19) Nucleocapsid Antibody (biotin)
9103-biotin-01mg 0.1 mg
EUR 495.22
Description: Coronavirus disease 2019 (COVID-19), formerly known as 2019-nCoV acute respiratory disease, is an infectious disease caused by SARS-CoV-2, a virus closely related to the SARS virus. The disease is the cause of the 2019–20 coronavirus outbreak (1). SARS-CoV-2 is the seventh member of the enveloped, positive-stranded RNA viruses that are able to infect humans. The SARS-CoV-2 genome, like other coronaviruses, encodes for multiple structural and nonstructural proteins. The structural proteins include spike protein (S), envelope protein (E), membrane glycoprotein (M), nucleocapsid phosphoprotein (N), and the nonstructural proteins include open reading frame 1ab (ORF1ab), ORF3a, ORF6, ORF7a, ORF8, and ORF10 (2). Nucleocapsid (N) protein is the most abundant protein of coronavirus. It is also one of the major structural proteins and is involved in the transcription and replication of viral RNA, packaging of the encapsidated genome into virions (3), and interference with cell cycle processes of host cells (4). Moreover, in many coronaviruses, including SARS-CoV, the N protein has high immunogenic activity and is abundantly expressed during infection (5). It can be detected in various patient samples including nasopharyngeal aspirate, urine, and fecal. Both S and N proteins may be potential antigens for serodiagnosis of COVID-19, just as many diagnostic methods have been developed for diagnosing SARS based on S and/or N proteins (6).

SARS-CoV-2 (COVID-19) Membrane Antibody (biotin)
9157-biotin-002mg 0.02 mg
EUR 191.42
Description: Coronavirus disease 2019 (COVID-19), formerly known as 2019-nCoV acute respiratory disease, is an infectious disease caused by SARS-CoV-2, a virus closely related to the SARS virus. The disease is the cause of the 2019–20 coronavirus outbreak (1). SARS-CoV-2 is the seventh member of the enveloped, positive-stranded RNA viruses that are able to infect humans. The SARS-CoV-2 genome, like other coronaviruses, encodes for multiple structural and nonstructural proteins. The structural proteins include spike protein (S), envelope protein (E), membrane glycoprotein (M), nucleocapsid phosphoprotein (N), and the nonstructural proteins include open reading frame 1ab (ORF1ab), ORF3a, ORF6, ORF7a, ORF8, and ORF10 (2).The membrane (M) protein or matrix protein is the most abundant structural protein and defines the shape of the viral envelope (3). It is an integral membrane protein involved in the budding of the viral particles and interacts with S (Spike) protein. It involves in organization of the nucleoprotein inside, which includes many copies of the N (nucleocapsid) protein bound to the genomic RNA. The M protein holds dominant cellular immunogenicity and has been determined as a protective antigen in humoral responses, which suggests it would serve as a potential target in vaccine design (4).

SARS-CoV-2 (COVID-19) Membrane Antibody (biotin)
9157-biotin-01mg 0.1 mg
EUR 495.22
Description: Coronavirus disease 2019 (COVID-19), formerly known as 2019-nCoV acute respiratory disease, is an infectious disease caused by SARS-CoV-2, a virus closely related to the SARS virus. The disease is the cause of the 2019–20 coronavirus outbreak (1). SARS-CoV-2 is the seventh member of the enveloped, positive-stranded RNA viruses that are able to infect humans. The SARS-CoV-2 genome, like other coronaviruses, encodes for multiple structural and nonstructural proteins. The structural proteins include spike protein (S), envelope protein (E), membrane glycoprotein (M), nucleocapsid phosphoprotein (N), and the nonstructural proteins include open reading frame 1ab (ORF1ab), ORF3a, ORF6, ORF7a, ORF8, and ORF10 (2).The membrane (M) protein or matrix protein is the most abundant structural protein and defines the shape of the viral envelope (3). It is an integral membrane protein involved in the budding of the viral particles and interacts with S (Spike) protein. It involves in organization of the nucleoprotein inside, which includes many copies of the N (nucleocapsid) protein bound to the genomic RNA. The M protein holds dominant cellular immunogenicity and has been determined as a protective antigen in humoral responses, which suggests it would serve as a potential target in vaccine design (4).

SARS-CoV-2 (COVID-19) Spike S1 Antibody (biotin)
9083-biotin-002mg 0.02 mg
EUR 191.42
Description: Coronavirus disease 2019 (COVID-19), formerly known as 2019-nCoV acute respiratory disease, is an infectious disease caused by SARS-CoV-2, a virus closely related to the SARS virus (1). The disease is the cause of the 2019–20 coronavirus outbreak (2). The structure of 2019-nCoV consists of the following: a Spike protein (S), hemagglutinin-esterease dimer (HE), a membrane glycoprotein (M), an envelope protein (E) a nucleoclapid protein (N) and RNA. Coronavirus invades cells through Spike (S) glycoproteins, a class I fusion protein. It is the major viral surface protein that coronavirus uses to bind to the human cell surface receptor. It also mediates the fusion of host and viral cell membrane, allowing the virus to enter human cells and begin infection (3). The spike protein is the major target for neutralizing antibodies and vaccine development (4). The protein modeling suggests that there is strong interaction between Spike protein receptor-binding domain and its host receptor angiotensin-converting enzyme 2 (ACE2), which regulate both the cross-species and human-to-human transmissions of COVID-19 (5). The recent study has shown that the SARS-CoV-2 spike protein binds ACE2 with higher affinity than SARS-CoV spike protein (6).

SARS-CoV-2 (COVID-19) Spike S1 Antibody (biotin)
9083-biotin-01mg 0.1 mg
EUR 495.22
Description: Coronavirus disease 2019 (COVID-19), formerly known as 2019-nCoV acute respiratory disease, is an infectious disease caused by SARS-CoV-2, a virus closely related to the SARS virus (1). The disease is the cause of the 2019–20 coronavirus outbreak (2). The structure of 2019-nCoV consists of the following: a Spike protein (S), hemagglutinin-esterease dimer (HE), a membrane glycoprotein (M), an envelope protein (E) a nucleoclapid protein (N) and RNA. Coronavirus invades cells through Spike (S) glycoproteins, a class I fusion protein. It is the major viral surface protein that coronavirus uses to bind to the human cell surface receptor. It also mediates the fusion of host and viral cell membrane, allowing the virus to enter human cells and begin infection (3). The spike protein is the major target for neutralizing antibodies and vaccine development (4). The protein modeling suggests that there is strong interaction between Spike protein receptor-binding domain and its host receptor angiotensin-converting enzyme 2 (ACE2), which regulate both the cross-species and human-to-human transmissions of COVID-19 (5). The recent study has shown that the SARS-CoV-2 spike protein binds ACE2 with higher affinity than SARS-CoV spike protein (6).

SARS-CoV-2 (COVID-19) Spike RBD Antibody (biotin)
9087-biotin-002mg 0.02 mg
EUR 191.42
Description: Coronavirus disease 2019 (COVID-19), formerly known as 2019-nCoV acute respiratory disease, is an infectious disease caused by SARS-CoV-2, a virus closely related to the SARS virus (1). The disease is the cause of the 2019–20 coronavirus outbreak (2). The structure of 2019-nCoV consists of the following: a Spike protein (S), hemagglutinin-esterease dimer (HE), a membrane glycoprotein (M), an envelope protein (E) a nucleoclapid protein (N) and RNA. Coronavirus invades cells through Spike (S) glycoproteins, a class I fusion protein. It is the major viral surface protein that coronavirus uses to bind to the human cell surface receptor. It also mediates the fusion of host and viral cell membrane, allowing the virus to enter human cells and begin infection (3). The spike protein is the major target for neutralizing antibodies and vaccine development (4). The protein modeling suggests that there is strong interaction between Spike protein receptor-binding domain and its host receptor angiotensin-converting enzyme 2 (ACE2), which regulate both the cross-species and human-to-human transmissions of COVID-19 (5). The recent study has shown that the SARS-CoV-2 spike protein binds ACE2 with higher affinity than SARS-CoV spike protein (6).
To our greatest data, this research represents the primary try to judge the impact of a phage as a organic management agent throughout ontogenetic growth of longfin yellowtail larvae. KEY POINTS: • Phages can be utilized towards proliferation of Vibrio in fish cultures. • Seriola consists of a number of essential business fish species attributable to its speedy progress. • Phages don’t trigger vital modifications in the related microbiota.